Vital Signs - Impact of 'Intended Use' On New Diagnostics


Regular Price: USD 1,500.00

Special Price USD 1,050.00

30% OFF

* Required Fields

Regular Price: USD 1,500.00

Special Price USD 1,050.00


Be the first to review this product

This issue of Vital Signs, released on December 22, 2008, provides an strategic overview of the impact of intended use on new clinical diagnostics. Additionally, a company spotlight is provided for InfraReDx, an emerging medical diagnostics company. Reimbursement and regulatory news from the FDA is also provided for the week of December 8, 2008.

Table of Contents

Vital Signs - Impact of "Intended Use" On New DiagnosticsVital Signs: 22 December 2008This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.